IRVING, Texas, Carrington Laboratories, Inc. (Nasdaq: CARN) announced that former U.S. Attorney General Edwin Meese III has been elected to the company’s board of directors.Meese, 71, joins the existing five-member board.
“We are gratified that a person of Ed Meese’s substantial legal and political expertise and uncompromising commitment to the highest ethical principles is joining our board,” said George DeMott, chairman of the board. “He brings the kind of specialized leadership we require in these increasingly complex times, not only in terms of the regulatory challenges businesses such as ours now face but also in meeting the new and increased obligations of public companies in the present securities environment. In addition to his extensive legal experience, Ed has a broad background in legislative and public policy matters as well as in international affairs.”
Meese was among President Ronald Reagan’s most important advisors. As chairman of the Domestic Policy Council and the National Drug Policy Board, and as a member of the National Security Council, he played a key role in the development and execution of domestic and foreign policy. Currently, he is Ronald Reagan Distinguished Fellow in Public Policy at The Heritage Foundation in Washington, D.C., a conservative research and educational institute—a think tank—whose mission is to formulate and promote conservative public policies based on the principles of free enterprise, limited government, individual freedom, traditional American values, and a strong national defense.Meese is also chairman of the Foundation’s Center for Legal and Judicial Studies.
Meese is a Distinguished Visiting Fellow at the Hoover Institution, Stanford University, and a Distinguished Senior Fellow at the Institute of United States Studies, University of London. During the 1970s, Meese was Director of the Center for Criminal Justice Policy and Management and Professor of Law at the University of San Diego. He earlier served as Chief of Staff for then-Governor Reagan and was a local prosecutor in California. Meese is a retired colonel in the U.S. Army reserve. He earned his B.A. from Yale University and his J.D. from the University of California, Berkeley.
I’m impressed with Carrington’s board and its research and development efforts,” Meese said. “The research on nasal delivery of drugs by Carrington’s DelSite subsidiary, particularly, is cutting-edge technology that I believe has considerable promise.”
Carrington Laboratories, Inc., is an ISO 9001-certified, research-based biopharmaceutical company currently utilizing naturally occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care; manufacture and market the nutraceutical raw materials Manapol® and Hydrapol™; and market consumer products under the AloeCeuticals® brand. Carrington's technology is protected by more than 120 patents in 26 countries. Select products are honored with the internationally coveted CE mark, recognized by more than 20 countries around the world.
Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the company's management; delays or problems in production; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission, including the Form 10K filed May 14, 2003.
Carlton E. Turner, Carrington Laboratories
President and CEO
(972) 518-1300 or (800) 527-5216
Karl Plath or Brien Gately
The Investor Relations Company